Machine-learning multi-omics links gut metabolites to GPCR targets and tau changes in Alzheimer’s patient-derived neurons
A machine-learning and multi-omics framework screened 1.09 million pairs across 408 human GPCRs and 335 gut microbial metabolites. It prioritized orphan receptor GPR84 and the metabolite triacanthine, which activated GPR84 in a cell assay. In Alzheimer’s patient-derived iPSC neurons, agmatine reduced C3AR and tau markers, while phenethylamine reduced phosphorylated and total tau in the reported experiments.
Technology: Extra Trees machine-learning model integrated with molecular docking, multi-omics and Mendelian-randomization analyses
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: It prioritized orphan receptor GPR84 and the metabolite triacanthine, which activated GPR84 in a cell assay.
- Still unknown: The metabolite–receptor screen is computational and many pairs remain predictions. Receptor activation was tested in a cell assay and tau-marker effects in patient-derived neurons; these experiments do not demonstrate clinical benefit, in-vivo efficacy or that altered tau markers translate to disease modification. Mendelian-randomization results and model scores are not proof of causality.
- AI role: The ML model ranked predicted metabolite–GPCR associations over a large search space; multi-omics and genetic analyses prioritized Alzheimer’s-related receptors and metabolites. These predictions guided follow-up assays, including triacanthine activation of GPR84 and testing agmatine and phenethylamine in patient-derived neurons.
Evidence sources: https://www.sciencedirect.com/science/article/pii/S221112472400456X
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 45 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.